CarlaMarie(Lichtenberger)NesterMDMSA, FASN
Nephrology • Iowa City, IAProfessor of Internal Medicine and Pediatrics, University Iowa,Carver College of Medicine
Dr. Nester is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
285 Newton Road
5294 CBRB
Iowa City, IA 52241Phone+1 319-335-2214Fax+1 319-384-9616
Education & Training
University of North Carolina HospitalsFellowship, Nephrology, 2003 - 2007- University of North Carolina HospitalsFellowship, Pediatric Nephrology, 2003 - 2007
- University of North Carolina HospitalsResidency, Internal Medicine/Pediatrics, 1998 - 2002
Pennsylvania State University College of MedicineClass of 1998
Certifications & Licensure
IA State Medical License 2007 - 2025
NC State Medical License 1999 - 2007
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Nephrology
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Nephrology
Publications & Presentations
PubMed
- 1 citationsIptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 Glomerulopathy.Carla M Nester, Ute Eisenberger, Alexandre Karras, Moglie le Quintrec, Liz Lightstone
Kidney International Reports. 2025-02-01 - Extrarenal manifestations of atypical hemolytic uremic syndrome: a systematic review and meta-analysis.Kush Doshi, Abdel Yusuf, Christoph Licht, Olivia Boyer, Carla Nester
Pediatric Research. 2024-12-15 - 5 citationsAn expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working Group.Carla M Nester, David L Feldman, Richard Burwick, Spero Cataland, Shruti Chaturvedi
Kidney International. 2024-09-01
Press Mentions
First Drug Approved for Ultra-Rare Kidney DiseaseMarch 21st, 2025- Novartis Oral Fabhalta Secures USFDA Okay for Adults with C3 GlomerulopathyMarch 20th, 2025
- Novartis Receives Third FDA Approval for Oral Fabhalta® (Iptacopan) – the First and Only Treatment Approved in C3 Glomerulopathy (C3G)March 20th, 2025
- Join now to see all
Grant Support
- C3 Glomerulopathy -- A Collaborative StudyUNIVERSITY OF IOWA2017–2027
- C3 Glomerulopathy -- A Collaborative StudyUNIVERSITY OF IOWA2017–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
